Skip to main content

Development and evaluation of a quantitative imaging technique for assessment of nanoparticle drug delivery across the blood-brain barrier: Applications for brain cancer therapeutics

Objective

The partners wish to build a long term European, Industry-Academia consortium, to work on the problem of delivering therapeutic agents, e.g. for brain cancer, across the blood-brain barrier (BBB) at the efficacious dose. Current treatment options for brain cancer are limited with patients having a poor prognosis. One of the major hurdles is the BBB which prevents effective doses of drugs reaching the site of disease. There is thus a major need for technologies that can successfully overcome such a hurdle without having a negative effect on safety and tolerability. Pharmidex have developed a drug delivery system that transiently and reversibly opens the BBB to entry of compounds into the brain without inducing tissue injury. It is based on patented lipid-like structures and has been shown to deliver both small molecules and large proteins effectively into the brain. The lead delivery compound for brain cancer appears to be safe and well tolerated on the basis of pre-clinical testing. We initially seek to determine the mechanism of action of the technology for penetrating the BBB; application to different therapeutic agents as well as development of reliable brain cancer animal models to quantify efficacy of nanoparticle-based therapy using imaging technology. We believe this novel delivery technology will be a unique drug discovery tool with the potential to enhance efficacy of established agents, reduce systemic exposure of the chemotherapeutic agent, thus minimising both the on/off-target toxicity through enhancement of drug absorption at the target site. Besides its scientific objectives, OncoNanoBBB will provide a framework for cooperation and knowledge sharing between a pharmaceutical industry and two academic institutions with complementary expertise in project objectives, as well as dissemination of project outcomes.

Field of science

  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-PEOPLE-2011-IAPP
See other projects for this call

Funding Scheme

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Coordinator

TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS
Address
Agiou Spyridonos 28 Kai Milou 1
122 10 Aigaleo
Greece
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 256 574
Administrative Contact
Ifigeneia Anastasakou (Ms.)

Participants (2)

Pharmidex Pharmaceutical Services Limited
United Kingdom
EU contribution
€ 487 803
Address
Hanover Street 14 Floor 3
W1S 1RR London
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Mo Alavijeh (Dr.)
UNIVERSITY OF BRIGHTON
United Kingdom
EU contribution
€ 105 581
Address
Lewes Road Mithras House
BN2 4AT Brighton
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Sergey Mikhalovsky (Prof.)